Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Высокочувствительное измерение кардиальных тропонинов: алгоритмы, интерпретация, клинические последствия

https://doi.org/10.33667/2078-5631-2020-7-30-41

Полный текст:

Аннотация

Обзор текущих направлений в использовании высокочувствительного измерения тропонинов (ВЧТн) в кардиологии и неотложной медицине. Особое внимание уделено аналитическим характеристикам ВЧТн-тестов и алгоритмам серийных ВЧ-измерений, применяемым для диагностики различных типов инфарктов миокарда, неишемических миокардиальных повреждений, стабильной и нестабильной стенокардии, сердечной недостаточности, кардиомиопатии Такоцубо, миокардита, инфекционного эндокардита перикардита. Рассмотрено также использование ВЧ-тестов для выявления миокардиальных повреждений у пациентов с сепсисом, пневмонией, ренальными патологиями, инсультом, а также у критических, госпитализированных и амбулаторных пациентов и у лиц общей популяции.

Об авторе

В. В. Вельков
АО «ДИАКОН»
Россия

к. б. н., директор по науке

г. Пущино, Московская область



Список литературы

1. Thygesen K, Alpert JS, Jaffe AS et al. Third Universal Definition of Myocardial Infarction. Circulation. 2012; 126 (16): 2020–35.

2. Thygesen K, Alpert JS, Jaffe AS et al. Fourth Universal Definition of Myocardial Infarction. J Am Coll Cardiol. 2018 72: 2231–2264. (Русский перевод. www.diakon-lab.ru/files/4%20%D0%BE%D0%BF%D1%80%D0%B5%D0%B4%D0%B5%D0%BB%D0%B5%D0%BD%D0%B8%D0%B5%20%D0%98%D0%9C%202018.pdf)

3. Collinson P. Troponin in Suspected Coronary Artery Disease Headed Toward a New Paradigm in Cardiac Biomarkers? J Am Coll Cardiol. 2019; 73 (3): 261–263.

4. Lippi G. The Irreplaceable Value of Laboratory Diagnostics: Four Recent Tests that have Revolutionized Clinical Practice. EJIFCC 2019,30 (1): 7–13.

5. Januzzi JL Jr, Mahler SA, Christenson RH et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. JACC Scientific Expert Panel J Am Coll Cardiol. 2019; 73 (9): 1059–1077.

6. Wu AHB, Christenson RH, Greene DN, et al. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2018; 64 (4): 645–655.

7. Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37 (3): 267–315.

8. Клинические рекомендации по диагностике и лечению больных с острым коронарным синдромом без подъема сегмента ST электрокардиограммы. Кардиологический вестник, 2017, т. XIV. № 3, с. 3–28.

9. Christenson RH, Mullins K, Duh SH. Validation of high-sensitivity performance for a United States Food and Drug Administration cleared cardiac troponin I assay. Clin Biochem. 2018; 56: 4–10.

10. Westermann D, Neumann JT, Sörensen NA et al. High-sensitivity assays for troponin in patients with cardiac disease. Nat. Rev.Cardiol 2017; 14 (8): 472–483.

11. Lippi G, Cervellin G. Diagnosing myocardial injury in the high-sensitivity troponin era Emergency Care Journal 2018; 14: 7834.

12. Andruchow JE, Kavsak PA, McRae A. Contemporary Emergency Department Management of Patients with Chest Pain: A Concise Review and Guide for the High-Sensitivity Troponin Era, Can J Cardiol. 2018; 34 (2): 98–108.

13. Eggers KM, Jernberg T, Ljung L et al. High-Sensitivity Cardiac Troponin -Based Strategies for the Assessment of Chest Pain Patients–A Review of Validation and Clinical Implementation Studies. Clin Chem. 2018 64 (11): 1572–1585.

14. Keller T, Hamm CW. High sensitivity cardiac troponin assays: finally ready for prime time? Nat Rev Cardiol. 2019; 16 (3): 135–136.

15. Goeddel L, Hopkins AM, Fernando DR et al. Analysis of the 4th Universal Definition of Myocardial Infarction – Key Concepts and Perioperative Implications. J. Cardiothorac. Vasc. Anesth. 2019, Jan 11.

16. Twerenbold R, Gimenez M R, Nestelberger T. Optimising the early rule-out and rule-in of myocardial infarction using biomarkers. Cardiovasc Med. 2019; 22: w02010.

17. Layfield C, Rose J, Alford A, et al. Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review. Clin Biochem. 2015; 48 (4–5): 204–12.

18. Le RD, Kosowsky JM, Landman AB et al. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting. Am J Emerg Med. 2015; 33 (1): 72–5.

19. Lippi G, Sanchis-Gomar F. “Ultra-sensitive” cardiac troponins: Requirements for effective implementation in clinical practice. Biochem Med (Zagreb). 2018; 28 (3), 030501.

20. Gore MO, Seliger SL, Defilippi CR et al. Ageand sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014; 63 (14): 1441–8.

21. Hickman PE, Potter JM, Aroney C et al. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta. 2010; 411: 318–323.

22. van Wijk XMR, Claassen S, Enea NS et al. Cardiac troponin I is present in plasma of type 1 myocardial infarction patients and patients with troponin I elevations due to other etiologies as complex with little free I. Clin Biochem. 2019. pii: S 0009–9120(19)30034.7.

23. Apple FS. Standardization of cardiac troponin I assays will not occur in my lifetime. Clin Chem. 2012: 58: 1 169–171.

24. Implementing high-sensitivity cardiac troponin assays in ptactice. IFCC Task Force on Clinical application of cardiac biomarkers. 2014. www.ifcc.org/media/259732/201405_TF_CB_IFCC_Implementing%20hs_pocket%20format.pdf.

25. High Sensitivity Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer IFCC Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB) www.ifcc.org/media/463453/HighSensitivityCardiacTroponinI_T_AssayAnalytical-Characteristics_v060617.pdf.

26. Collinson PO, Saenger AKm Apple FS, on behalf of the IFCC C–CB. High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers. Clin Chem Lab Med. 2019; 57 (5): 623–632.

27. McCarthy CP, Raber I, Chapman AR et al. Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays. A Practical Approach for Clinicians. JAMA Cardiol. 2019 Aug 7.

28. Mueller M, Vafaie M, Biener M, Cardiac troponin T. Circ J. 2013; 77 (7): 1653–61.

29. Вельков В. В., Ишемическое и неишемическое повышение высокочувствительных тропонинов: интерпретация, оценка рисков, терапия. «Клинико-лабораторный консилиум». Научно-практический журнал, 2013, 2–3 (46), 20–38. diakonlab.ru/files/Docs/SciArticles/Mag2–3%2846%292013%28Crop-2%29.pdf.

30. Newby LK, Jesse RL, Babb JD et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012; 60 (23): 2427–63.

31. Casagranda I, Cavazza M, Clerico A. et al. Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Clin Chem Lab Med. 2013; 51 (9): 1727–37.

32. Pickering JW, Than MP, Cullen L et al. Rapid rule-out of acute myocardial infarction with A single high-sensitivity cardiac troponin T measurement below the limit of detection: a collaborative meta-analysis. Ann Intern Med 2017; 166: 715–2.

33. Hoeller R, Rubini Giménez M et al. Normal presenting levels of high-sensitivity troponin and myocardial infarction. Heart. 2013; 99 (21): 1567–72.

34. Mueller M, Biener M, Vafaie M, et al. Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem 2012; 58: 209–18.

35. Boeddinghaus J, Nestelberger T, Badertscher P et al. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019; 380 (26): 2529–2540.

36. Nestelberger T Wildi K, Boeddinghaus J et al. Characterization of the observe zone of the ESC 2015 high-sensitivity cardiac troponin 0 h/1 h-algorithm for the early diagnosis of acute myocardial infarction. Int J Cardiol.2016; 207: 238–45.

37. Giannitsis E, Katus HA. Troponins: established and novel indications in the management of cardiovascular disease. Heart 2018; 104: 1714–1722.

38. Twerenbold R, Costabel JP, Nestelberger T et al. Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction. J Am Coll Cardiol 2019; 74: 483–94.

39. Sandoval Y Jaffe AS, Type 2 Myocardial Infarction. JACC Review Topic of the Week. Am Coll Cardiol. 2019; 73: 1846–60.

40. Lee KK, Shah ASV. High-sensitivity cardiac troponin – a double-edged sword. Eur Heart J Qual Care Clin Outcomes. 2019 Jul 2.

41. Greenslade JH, Adikari T, Mueller C, et al. Characteristics and occurrence of type 2 myocardial infarction in emergency department patients: a prospective study. Emerg Med J; 2018; 35: 169–75.

42. Nestelberger T, Boeddinghaus J, Badertscher P, et al. Effect of definition on incidence and prognosis of type 2 myocardial infarction. J Am Coll Cardiol 2017; 70: 1558–68.

43. Shah AS, McAllister DA, Mills R et al. Sensitive Troponin Assay and the Classification of Myocardial Infarction. Am J Med. 2015; 128 (5): 493–501.

44. Lambrecht S, Sarkisian L Saaby L et al. Different Causes of Death in Patients with Myocardial Infarction Type 1, Type 2, and Myocardial Injury. Am J Med; 2018 131 (5): 548–554.

45. Etaher A, Gibbs OJ, Saad YM et al. Type-II myocardial infarction and chronic myocardial injury rates, invasive management, and 4-yearmortality am ong consecutivepatients undergoing high-sensitivity troponin T testing in the emergency department. Eur Heart J Qual Care Clin Outcomes, 2019 May 20. pii: qcz019.

46. Sandoval Y, Thordsen SE, Smith SW et al. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Heart J Acute Cardiovasc Care. 2014; 3: 317–25.

47. Myhre PL, Omland T, Sarvari SI et al. Cardiac Troponin T Concentrations, Reversible Myocardial Ischemia, and Indices of Left Ventricular Remodeling in Patients with Suspected Stable Angina Pectoris: a DOPPLER-CIP Substudy. Clin Chem. 2018; 64 (9): 1370–1379.

48. Adamson PD, Hunter A, Madsen DM et al.. High sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes 2018; 11: e004227.

49. Vavik V, Pedersen EKR, Svingen GFT et al. Usefulness of Higher Levels of Cardiac Troponin T in Patients With Stable Angina Pectoris to Predict Risk of Acute Myocardial Infarction. Am J Cardiol. 2018; 122 (7): 1142–1147.

50. Braunwald E. Unstable angina. A classification. Circulation. 1989; 80: 410–414.

51. Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000; 102: 118–122.

52. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002; 90: 358–363.

53. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29: 43–8.

54. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin Tlevels. c7E 3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623–9.

55. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286: 2405–12.

56. Sandoval Y, Apple FS, Smith SW. High-sensitivity cardiac troponin assays and unstable angina Eur Heart J Acute Cardiovasc Care. 2018 Mar; 7 (2): 120–128.

57. Januzzi JL, Sharma U, Zakroysky P, et al. Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. Am Heart J. 2015; 169 (4): 572–8.

58. D’Souza M, Sarkisian L, Saaby L et al. The diagnosis of unstable angina pectoris has declined markedly with the advent of more sensitive troponin assays. Am J Med. 2015; 128 (8): 852–60.

59. Braunwald E, Morrow DA, Unstable Angina Is It Time for a Requiem?. Circulation. 2013; 127: 2452–2457.

60. Giannitsis E, Biener M, Hund H et al., Management and outcomes of patients with unstable angina with undetectable, normal, or intermediate hsTnT levels. Clin Res Cardiol. 2019 Jul 19.

61. Rambarat CA, Elgendy IY, Pepine CJ et al. Does unstable angina still exist? Heart Metab. 2018; 75: 15–18.

62. Yousufuddin M, Abdalrhim AD, Wang Z et al. Cardiac troponin in patients hospitalized with acute decompensated heart failure: a systematic review and meta-analysis. J Hosp Med. 2016; 11: 446–454.

63. Pang PS, Teerlink JR, Voors AA et al. Use of high-sensitivity troponin T to identify patients with acute heart failure at lower risk for adverse outcomes: an exploratory analysis from the RELAX-AHF Trial. JACC Heart Fail. 2016; 4: 591–599.

64. Pandey A, Golwala H, Sheng S et al. Factors associated with and prognostic implications of cardiac troponin elevation in decompensated heart failure with preserved ejection fraction: findings from the American Heart Association get with the guidelines-heart failure program. JAMA Cardiol. 2017; 2: 136–145.

65. Evans JDW, Dobbin SJH, Pettit SJ. High-Sensitivity Cardiac Troponin and New-Onset Heart Failure A Systematic Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart Failure Events., JACC Heart Fail. 2018; 6 (3): 187–197.

66. Bozkurt B. High-Sensitivity Cardiac Troponin: From Patient Phenotypes to Clinical Events in Patients With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2018; 7: e011174.

67. Harrison N, Favot M, Levy P. The Role of Troponin for Acute Heart Failure. Curr Heart Fail Rep. 2019; 16 (1): 21–31.

68. Kato K, Lyon AR, Ghadri J-R et al. Takotsubo syndrome: aetiology, presentation and treatment. Heart 2017; 103: 1461–1469.

69. Ghadri JR Sarcon A Diekmann J et al. Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. Eur Heart J. 2016; 37 (37): 2823–2829.

70. Fröhlich GM, Schoch B, Schmid F. Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy. Int J Cardiol. 2012; 154, 328–332.

71. Doyen D, Moceri, Chiche O et al. Cardiac biomarkers in Takotsubo cardiomyopathy. Int J Cardiol.2014; 174 (3): 798–801.

72. Gopalakrishnan P, Zaid R, Sardar M et al. Takotsubo cardiomyopathy: Pathophysiology and role of cardiac biomarkers in differential diagnosis. World J Cardiol. 2017; 9 (9): 723–730.

73. Smith SC, Ladenson JH, Mason JW et al. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 1997; 95 (1), 163–168.

74. Pierre A Monney, Sekhri N et al. Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis. Heart 2011; 97: 1312e1318.

75. Eisenberg MA, Green-Hopkins I, Alexander ME, et al. Cardiac troponin T as a screening test for myocarditis in children. Pediatr Emerg Care. 2012; 28: 1173–1178.

76. Rodriguez-Gonzalez M, Sanchez-Codez MI, Lubian-Gutierrez M et al Clinical presentation and early predictors for poor outcomes in pediatric myocarditis: A retrospective study. World J Clin Cases. 2019; 7 (5): 548–561.

77. Cahill TJ, Baddour LM, Habib G et al. Challenges in Infective Endocarditis. J Am Coll Cardiol. 2017; 69: 325–44.

78. Ipek EG, Guray Y, Acar B et al. The usefulness of serum troponin levels to predict 1-year survival rates in infective endocarditis. Int J Infect Dis. 2015; 34, 71–75.

79. 79.Thoker ZA, Khan KA, Rashid I et al. Correlation of cardiac troponin I levels with infective endocarditis and its adverse clinical outcomes. Int J Cardiol. 2016; 222, 661–664.

80. McNamara N, Ibrahim A, Satti Z et. al. Acute pericarditis: a review of current diagnostic and management guidelines. Future Cardiol. 2019; 15 (2): 119–126.

81. Imazio M. Pericarditis with troponin elevation: is it true pericarditis and a reason for concern? J Cardiovasc Med (Hagerstown 2014; 15: 73–77.

82. Gamaza-Chulián S, León-Jiménez J, Recuerda-Núñez M et al. Cardiac troponin T in acute pericarditis J Cardiovasc Med (Hagerstown). 2014 Jan; 15 (1): 68–72.

83. Daniel M, Abers MS, Corrales-Medina VF et al. Acute Infection and Myocardial Infarction. N Engl J Med 2019; 380: 171–6.

84. Lee YJ, Lee H, Park JS et al. Cardiac troponin I as a prognostic factor in critically ill pneumonia patients in the absence of acute coronary syndrome. J Crit Care. 2015; 30 (2): 390–4.

85. Violi F, Cangemi R, Falcone M et al. Cardiovascular complications and short term mortality risk in community-acquired pneumonia. Clin Infect Dis 2017; 64: 1486–93.

86. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015; 313: 264–74.

87. Vestjens SM, Spoorenberg SM, Rijkers GT, et al; Ovidius Study Group High-sensitivity cardiac troponin T predicts mortality after hospitalization for community-acquired pneumonia. Respirology 2017; 22: 1000–1006.

88. Frencken JF, van Baal L, Kappen TH et al. Myocardial injury in critically ill patients with community-acquired pneumonia: a cohort study. Ann Am Thorac Soc 2019; 16: 606–612..

89. Hussain N. Elevated cardiac troponins in setting of systemic inflammatory response syndrome, sepsis, and septic shock. ISRN Cardiol. 2013; 2013: 723435.

90. Bessiere F, Khenifer S, Dubourg J et al. Prognostic value of troponins in sepsis: a meta-analysis. Intensive Care Med 2013; 39 (7): 1181–9.

91. Clemente G, Tuttolomondo A, Colomba D et al. When sepsis affects the heart: A case report and literature review. World J Clin Cases. 2015; 3 (8): 743–50.

92. Sheyin O, Davies O, Duan W, et al. The prognostic significance of troponin elevation in patients with sepsis: a meta-analysis. Heart Lung. 2015; 44: 75–81.

93. Landesberg G, Jaffe AS, Gilon D et al. Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation. Crit Care Med. 2014; 42 (4): 790–800.

94. Bonk MP, Meyer NJ. Troponin I: A New Marker of Sepsis-induced Hypoperfusion? Ann Am Thorac Soc. 2019; 16 (5): 552–55.

95. Szczykowska J, Hryszko T, Naumnik B et al. Cardiac troponins in chronic kidney disease patients with special emphasis on their importance in acute coronary syndrom Adv Med Sci. 2019; 64 (1); 131–136.

96. Miller-Hodges E, Anand A, Shah ASV et al. High sensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. Circulation. 2018; 137: 425–435.

97. Twerenbold R, Badertscher P, Boeddinghaus J et al. 0/1-Hour triage algorithm for myocardial infarction in patients with renal dysfunction. Circulation. 2018; 137: 43–451.

98. van der Linden N, Cornelis T, Kimenai DM et al. Origin of Cardiac Troponin T Elevations in Chronic Kidney Disease Circulation. 2017; 136 (11): 1073–1075.

99. Kavsak P Worster A Shortt C et al. Performance of high-sensitivity cardiac troponin in the emergency department for myocardial infarction and a composite cardiac outcome across different estimated glomerular filtration rates. Clin Chim Acta. 2018; 479: 166–170.

100. Yang H, Liu J, Luo H et al. Improving the diagnostic accuracy of acute myocardial infarction with the use of high-sensitive cardiac troponin T in different chronic kidney disease stages. Sci Rep. 2017; 7: 41350.

101. Garimella PS, Lee AK, Ambrosius WT, et al. Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial. Eur Heart J. 2019 Jun 30. pii: ehz392.

102. van der Linden N, Cornelis T, Kimenai DM et al. Origin of Cardiac Troponin T Elevations in Chronic Kidney Disease. Circulation. 2017; 136 (11): 1073–1075.

103. Jensen JK, Atar D, Mickley H. Mechanism of troponin elevations in patients with acute ischemic stroke. Am. J. Cardiol. 2007; 99: 867–870.

104. Powers WJ, Rabinstein AA, Ackerson T et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association / American Stroke Association. Stroke. 2018; 49: e46–e110.

105. Mochmann H-C, Scheitz JF, Petzold GC et al. TRELAS Study Group. Coronary Angiographic Findings in Acute Ischemic Stroke Patients With Elevated Cardiac Troponin: The Troponin Elevation in Acute Ischemic Stroke (TRELAS) Study. Circulation. 2016; 133: 1264–1271.

106. Scheitz JF, Mochmann HC, Erdur H, et al. Prognostic relevance of cardiac troponin T levels and their dynamic changes measured with a high-sensitivity assay in acute ischaemic stroke: Analyses from the TRELAS cohort. Int J Cardiol. 2014, 177, 886–93.

107. Scheitz JF, Nolte CH, Laufs U et al. Application and interpretation of high-sensitivity cardiac troponin assays in patients with acute ischemic stroke. Stroke. 2015; 46: 1132–1140.

108. Schmidt-Pogoda A. Elevated troponin in acute ischemic stroke – a matter of debate? eso-stroke.org/strokeresearch/elevated-troponin-in-acute-ischemic-stroke-a-matter-of-debate.

109. Mariathas M, Alla R, Ramamoorthy S et al. True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study. BMJ 2019; 364: l729.

110. Yiadom MY, Jarolim P, Jenkins C et al. Diagnostic implications of an elevated troponin in the emergency department. Dis Markers. 2015; 2015: 157812.

111. Makam AN, Nguyen OK. Use of cardiac biomarker testing in the emergency department. JAMA Intern Med. 2015; 175 (1): 67–75.

112. Courtney D, Conway R, Kavanagh J et al., High-sensitivity troponin as an outcome predictor in acute medical admissions. Postgrad Med J. 2014 Jun; 90 (1064): 311–6.

113. Ostermann M, Lo J, Toolan M, et al. A prospective study of the impact of serial troponin measurements on the diagnosis of myocardial infarction and hospital and six-month mortality in patients admitted to ICU with non-cardiac diagnoses. Crit Care. 2014; 18 (2): R 62.

114. Lee KK. Noaman A Vaswani A et al., Prevalence, determinants and clinical associations of high-sensitivity cardiac troponin in patients attending the Emergency Department. Am. J Med. 2019; 132 (1): 110. e8–110. e21.

115. de Lemos JA, Drazner MH, Omland T et al.Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503–12.

116. Apple FS, Jaffe AS, Collinson P et al. on behalf of the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers. IFCC educational materials on selected analytical and clinical applications of high-sensitivity cardiac troponin assays. Clin Biochem. 2015; 48: 201–23.

117. Blankenberg S, Salomaa V, Makarova N et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J 2016; 37: 2428–37.

118. Willeit P, Welsh P, Evans JDW et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. J Am Coll Cardiol 2017; 70: 558–68.

119. Jia X, Sun W, Hoogeveen RC al. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019; 139 (23): 2642–2653.

120. Adamson PD Mills NL High-Sensitivity Troponin and the Selection of Patients for Cardiac Imaging in the Outpatient. Clin Chem. 2018; 64 (11): 1555–1557.

121. de Lemos JA. Technology Meets Opportunity: High-Sensitivity Troponin Testing for Screening Apparently Healthy Adults. Clin Chem. 2019; 65 (4): 593–594.

122. Lam, C.S.P, Castillo R, Ho DT et al., High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. Int J Cardiol. 2019; 282: 93–98.

123. Takahashi Y, Satoh M, Ohmomo H et al. Association between high-sensitivity cardiac troponin T and future cardiovascular incidence in a general Japanese population: Results from the Tohoku Medical Megabank Project. Biomarkers.2019; 24 (6): 566–57.

124. Lyngbakken MN, Rosjo H, Holmen OL et al Temporal Changes in Cardiac Troponin I Are Associated with Risk of Cardiovascular Events in the General Population: The Nord-Trшndelag Health Study. Clinl Chem. 2019; 65 (7): 871–881.

125. Welsh P, Preiss D, Shah ASV et al. Comparison Between High Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. Clin Chem. 2018; 64 (11): 1607–1616.

126. Everett BM, Zeller T, Glynn RJ, High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy Circulation. 2015; 131 (21): 1851–60.

127. Ford I, Shah AS, Zhang R et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol 2016; 68: 2719–28.

128. Katus H, Ziegler A, Ekinci O et al. Early diagnosis of acute coronary syndrome. Eur Heart J. 2017; 38 (41): 3049–3055.

129. Вельков В. В.. Революция в кардиологии; высокочувствительное измерение кардиальных тропонинов: «тропонин-отрицательных больше нет». Клинико-лабораторный консилиум, Научно-практический журнал 2011, № 4 (40), 24–43.

130. Dedic A, Lubbers MM, Schaap J et al. Coronary CT Angiography for Suspected ACS in the Era of High-Sensitivity Troponins: Randomized Multicenter Study. Am Coll Cardiol. 2016; 67 (1): 16–26.

131. Latta F, de Filippi C. Role for Cystatin C-Based Risk Stratification for Patients After Acute Coronary Syndrome in the Era of High Sensitivity Cardiac Troponin Assays. J Am Heart Assoc. 2018 Oct 16; 7 (20): e010589.

132. Yang S, Manjunath L, Willemink MJ et al.The role of coronary CT angiography for acute chest pain in the era of high-sensitivity troponins. J Cardiovasc Comput Tomogr. 2019 Jun 15.

133. Brzezinski RY, Milwidsky A, Shenhar-Tsarfaty S. Exercise-induced cardiac troponin in the era of high sensitivity assays: What makes our heart sweat? Int J Cardiol. 2019; 288: 19–21.

134. Del Carlo CH. Rule-out myocardial infarction in the high-sensitivity cardiac troponin era. Int J Cardiol. 2019; 288: 17–18.

135. Lanza GA, Melita V, Mencarelli E et al. Characteristics and in-hospital outcome of patients with no ST-segment elevation acute coronary syndrome and no obstructive coronary artery disease in the era of high-sensitivity troponins J Cardiovasc Med (Hagerstown). 2019; 20 (4): 210–214.

136. Muchtar E, Kumar SK, Gertz MA et al. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood. 2019; 133 (7): 763–766.

137. Chew PG, Frost F, Mullen L et al. A direct comparison of decision rules for early discharge of suspected acute coronary syndromes in the era of high sensitivity troponin Eur Heart J Acute Cardiovasc Care. 2019; 8 (5): 421–431.


Для цитирования:


Вельков В.В. Высокочувствительное измерение кардиальных тропонинов: алгоритмы, интерпретация, клинические последствия. Медицинский алфавит. 2020;(7):30-41. https://doi.org/10.33667/2078-5631-2020-7-30-41

For citation:


Velkov V.V. High sensitivity measurement of cardiac troponins: algorithms, interpretations, clinical consequences. Medical alphabet. 2020;(7):30-41. (In Russ.) https://doi.org/10.33667/2078-5631-2020-7-30-41

Просмотров: 22


ISSN 2078-5631 (Print)